Ekf Diagnostics Share Discussion Threads

[tongosti] 13/6/2022 15:19

Out flat chaps. Hardly enticing wider markets and share. Cash is King in this market - time to play the spectator.

[wan] 13/6/2022 09:24

EKF is indeed transitioning!

Put another way, one assumes that a good slug of that capacity will transition to Direct-to-Consumer test kits, which as previously covered, represents a substantial growth opportunity.

EKF have already stated that its facilities and knowledge is to be utilised to provide services to diagnostics developers in the US and UK, with part of EKF's updated Growth Strategy to invest in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses.

[se81] 13/6/2022 08:25

And importantly...

"The receipt of this cash payment is a significant move towards a clean break from COVID-related services for our Contract Manufacturing business as we transition into new areas"

[wan] 13/6/2022 08:11

A welcome update today on the improved and strong cash position, importantly which also reflects the successful execution of the Company's GBP4m buyback programme and the further GBP2.5m investment in Verici Dx.

According to my math, when taking those execution factors into consideration, effectively demonstrates the 'underlying' positive cash flow in the 5 months to 31 May.

[p1nkfish] 11/6/2022 10:56

I think we need to break through 38 as a weekly close and 42.5 on a monthly.

[tongosti] 10/6/2022 18:58

You're excused pal - just don't do it again will ya :)

[wan] 10/6/2022 09:34

I genuinely forgot to post this article last week -

Direct-to-Consumer medical testing is something all medical labs should embrace

As more patients request direct-to-consumer (DTC) lab tests, medical laboratories will need to reconfigure and upgrade key aspects of their business in order to serve these new healthcare consumers properly. No longer a pure business-to-business endeavor, labs are now finding themselves in the consumer market.
By J.T. RIPTON

June 1, 2022

As the healthcare industry continues to evolve, medical labs are finding themselves in a unique position. Historically one of the most under-recognized medical specialties, labs are now an essential part of the healthcare equation. According to the Centers for Disease Control and Prevention (CDC), 14 billion lab tests are ordered annually, with 70% of medical decisions dependent on their findings. As such, labs have become the tissue connecting physicians with the information they need to provide quality care.

But healthcare professionals aren’t the only ones ordering lab tests these days. The age of healthcare consumerism is changing the way patients access medical services. This is especially true when it comes to medical testing. Patients who now want more control over their care are taking the initiative and ordering medical tests for themselves.

As more patients request direct-to-consumer (DTC) lab tests, medical laboratories will need to reconfigure and upgrade key aspects of their business in order to serve these new healthcare consumers properly. No longer a pure business-to-business endeavor, labs are now finding themselves in the consumer market. Labs that want to grow and thrive as the paradigm shifts will need to plan accordingly.

Full story and a worthy read for further salient points and insights -


And unlike other labs, ADL should benefit from EKF also being the contract manufacturer for certain direct-to-consumer test kits, not to mention the potential use of proprietary EKF enzymes that can be produced in bulk scale for mass production of such test kits.

[tongosti] 09/6/2022 16:30

I agree on the balance of odds. For a proper recovery you will need wider markets to play ball as well (very tall order this is as chances are we are in the midst of a proper bear market). Hence my earlier comment about playing this over the shorter term.

[p1nkfish] 09/6/2022 15:34

I doubt this is the start of the "recovery proper" which I think we could see start early-mid autumn and back through 40p+.

[tongosti] 09/6/2022 12:01

Likewise pal

[p1nkfish] 09/6/2022 11:43

Each to their own. Enjoy!

[tongosti] 09/6/2022 11:33

Personal choice and all but I have found (been to hell and back, believe me) playing (a lot) for pennies is far safer than aim for the occasional pound. Not unlike predicting weather tomorrow is far safer than 10 years from now. In my view, pennies (when one plays for lots of them) have a way to compound much faster than (mythical) pounds than most would think.

[p1nkfish] 09/6/2022 11:10

So long as you holding is small compared to average daily else your exit will be less than ideally priced. Hold for me as reckon CAGR over 2 years will be attractive but not linear return.

[tongosti] 09/6/2022 09:53

On today's further rise, worth tightening the stop North and riding this on negligible risk. As the wise man said, it's all about timing in the universe we live in.

[wan] 09/6/2022 08:52

Edit to the above post - albeit it's only one among other EKF growth initiatives

[wan] 09/6/2022 08:32

Recall the following - US blood banks: DiaSpect Tm approved by FDA Center for Biologics Evaluation and Research (CBER)

Note that anaemia screening programmes and blood banking initiatives restarted post-pandemic.

Examples -

14 June is World Blood Donor Day


The official website of the US Military Health System -
With this simple act of generosity, you could be saving the life of someone’s brother, sister, parent, or friend. Find out where you can #ReadySetDonate today: militarydonor.com And thank you to all those who have already donated!


EKF's range of hemoglobin analyzers make blood donation and anemia screening easier -


Watch this space (albeit it's only one among other EKF growth initiatives).

[wan] 09/6/2022 07:53

I was impressed with EKF's Link, and todays RNS clearly lays it out as a key differentiator for both new and existing accounts.

This will also apply to new EKF point-of-care devices, or indeed be attractive to new distribution agreements, including private label distribution agreements, such as that already in place with McKesson in the US.

The introduction of EKF's Link connectivity software was one element of EKF's Growth Strategy, which will no doubt also assist the stated diversification and enhancement of their PoC portfolio, including entry into adjacent markets.

Insightful -

[p1nkfish] 09/6/2022 07:27

RNS on EKF Link has landed.

[tongosti] 08/6/2022 14:21

It just doesn't matter the reason why. All that matters is huge volumes showing a great level of interest. Since this is a perception game - volumes are Mr Market's way to tip his hand off. No guarantee of course (anything can happen in this game so managing risk via SL route is key). Wan - there is a time to go long and a time to go short. There is never a time to support one side indefinitely. Granted, it's a tall order pal.

[faz] 08/6/2022 13:53

3m shares traded so far today. A concerted decision by a few players or leaked info? It can wait til tomorrow to see if this is a fluke or not. The company has assets, £20m cash,trades profitably, and has secured a loyal customer base with a strategy for growth. So could attract a bid of around £200-£220m I suppose.

[tongosti] 08/6/2022 13:17

Chart is indeed conducive. Assuming wider markets play ball (big ask in the context of wider macro worries), this is indeed a good risk ward proposition on the long side ( for a change). An exploratory bet with a tight stop is not a bad idea. If it works great - if it doesn't that's what the stop is there for.

[wan] 08/6/2022 11:25

Regarding my final comment in post 2759/2760 - Put another way, highly specialised contract fermentation can apparently produce hard to replicate cannabinoids at commercial scale for consumer applications and pharmacological pipelines, which in turn, like hemp and its derivatives, will also require accurate testing in order to have accurate and appropriate consumer protection labelling, thus staying the right side of the FDA in terms of marketing and authorisation.

'Fermented' food for thought: Specialist cannabinoid production capability along with specialist authorised testing capability would appear to be very complimentary, and would thus appear to represent an attractive fit for companies producing next-generation natural ingredients.

Readers will note in post 2759 that ADL test plant material for Delta-9-THC, THCA and 9 other cannabinoids.